Pre-surgery chemotherapy with toripalimab for dMMR stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies whether adding toripalimab (an immune therapy) to chemotherapy before and around surgery can improve outcomes for people with certain mismatch repair–deficient stomach cancers. It mainly targets tumors that are dMMR and not HER2-positive.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (age 18–80) and able to move around (ECOG 0–1).
- Your cancer must be stomach or esophagus-stomach junction adenocarcinoma confirmed by biopsy.
- Your tumor must be mismatch repair–deficient (dMMR) on a test done on an endoscopy biopsy.
- Your cancer stage must be T2 to T4b with nearby lymph nodes involved, but no distant spread (M0).
- You must have adequate blood counts, liver, kidney, and blood-clotting test results for treatment.
- You must not have had any prior treatment for stomach cancer and must not have HER2-positive cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and an immunotherapy drug called toripalimab before and after surgery for a specific type of stomach cancer linked to the Epstein-Barr virus. It aims to see if this approach can improve treatment outcomes for patients with locally advanced disease.
This trial tests whether combining toripalimab (an immunotherapy) with celecoxib (an anti-inflammatory drug) can shrink locally advanced colorectal tumors that have specific genetic features (dMMR or MSI-H). It aims to help people who haven't had any prior treatment for their colorectal cancer.
This trial tests whether adding the immunotherapy drug Sintilimab to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It's for people with high-risk or advanced stage cancer that has a specific genetic feature (dMMR or MSI-H).
This trial studies a treatment given before surgery using toripalimab, with or without celecoxib, for colon or rectal cancer that has MSI-H or dMMR tumor features. It aims to shrink or control the cancer before the operation and compare whether adding celecoxib helps.
This trial tests whether giving an immunotherapy drug called toripalimab after surgery can lower the chance of colon cancer coming back. It is for people whose tumors have a specific genetic feature called mismatch repair deficiency (dMMR) and who have had their cancer completely removed.
This trial studies toripalimab (an immune system medicine) plus FLOT chemotherapy in people with stomach cancer that has grown locally but hasn’t spread to distant organs. It aims to improve control of the cancer and help more people have their tumors fully treated.
Hear when a new Adenocarcinoma of Esophagogastric Junction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.